NCT02186509 2025-04-30
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Phase 1 Completed
Clinical Trials
11 trialsNCT04085315 2024-06-10
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01924260 2022-08-02
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
University of California, Davis
Phase 1 Completed
NCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT01923337 2019-01-04
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
University of California, Davis
Phase 1 Completed
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02780011 2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1 Withdrawn
NCT01677559 2018-01-11
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT02700022 2017-11-20
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT02812056 2017-03-27
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
M.D. Anderson Cancer Center
Phase 1 Withdrawn